Detalles de la búsqueda
1.
SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20140178
2.
The spike-stabilizing D614G mutation interacts with S1/S2 cleavage site mutations to promote the infectious potential of SARS-CoV-2 variants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-492832
3.
Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22277885
4.
Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20101832
5.
Cluster of COVID-19 in northern France: A retrospective closed cohort study
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20071134
6.
SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22273175
7.
Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22272066
8.
Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised Patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21261766
9.
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21261769
10.
Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-B.1.1.7 or B.1.1.7 SARS-CoV-2 variants.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21257393
11.
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-516888
12.
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-475248
13.
Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-445838
14.
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22278699
15.
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20230508
16.
Sex differences in the decline of neutralizing antibodies to SARS-CoV-2
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20230466
17.
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430472
18.
Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-472630
19.
SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20068858
20.
Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-486719